Literature DB >> 25993379

Increasing pulmonary artery pulsatile flow improves hypoxic pulmonary hypertension in piglets.

Audrey Courboulin1, Chantal Kang2, Olivier Baillard3, Sebastien Bonnet1, Pierre Bonnet4.   

Abstract

Pulmonary arterial hypertension (PAH) is a disease affecting distal pulmonary arteries (PA). These arteries are deformed, leading to right ventricular failure. Current treatments are limited. Physiologically, pulsatile blood flow is detrimental to the vasculature. In response to sustained pulsatile stress, vessels release nitric oxide (NO) to induce vasodilation for self-protection. Based on this observation, this study developed a protocol to assess whether an artificial pulmonary pulsatile blood flow could induce an NO-dependent decrease in pulmonary artery pressure. One group of piglets was exposed to chronic hypoxia for 3 weeks and compared to a control group of piglets. Once a week, the piglets underwent echocardiography to assess PAH severity. At the end of hypoxia exposure, the piglets were subjected to a pulsatile protocol using a pulsatile catheter. After being anesthetized and prepared for surgery, the jugular vein of the piglet was isolated and the catheter was introduced through the right atrium, the right ventricle and the pulmonary artery, under radioscopic control. Pulmonary artery pressure (PAP) was measured before (T0), immediately after (T1) and 30 min after (T2) the pulsatile protocol. It was demonstrated that this pulsatile protocol is a safe and efficient method of inducing a significant reduction in mean PAP via an NO-dependent mechanism. These data open up new avenues for the clinical management of PAH.

Entities:  

Mesh:

Year:  2015        PMID: 25993379      PMCID: PMC4542540          DOI: 10.3791/52571

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  23 in total

Review 1.  An evidence-based approach to the management of pulmonary arterial hypertension.

Authors:  Stephen L Archer; Evangelos D Michelakis
Journal:  Curr Opin Cardiol       Date:  2006-07       Impact factor: 2.161

2.  Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.

Authors:  Nazzareno Galiè; Adam Torbicki; Robyn Barst; Philippe Dartevelle; Sheila Haworth; Tim Higenbottam; Horst Olschewski; Andrew Peacock; Giuseppe Pietra; Lewis J Rubin; Gerald Simonneau; Silvia G Priori; Maria Angeles Alonso Garcia; Jean-Jacques Blanc; Andrzej Budaj; Martin Cowie; Verconcia Dean; Jaap Deckers; Enrique Fernandez Burgos; John Lekakis; Bertil Lindahl; Gianfranco Mazzotta; Keith McGregor; João Morais; Ali Oto; Otto A Smiseth; Joan Albert Barbera; Simon Gibbs; Marius Hoeper; Marc Humbert; Robert Naeije; Joanna Pepke-Zaba
Journal:  Eur Heart J       Date:  2004-12       Impact factor: 29.983

3.  Nitric oxide and the lung.

Authors:  W M Zapol; S Rimar; N Gillis; M Marletta; C H Bosken
Journal:  Am J Respir Crit Care Med       Date:  1994-05       Impact factor: 21.405

4.  Reversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support.

Authors:  Guillermo Torre-Amione; Robert E Southard; Matthias M Loebe; Keith A Youker; Brian Bruckner; Jerry D Estep; Megan Tierney; George P Noon
Journal:  J Heart Lung Transplant       Date:  2009-09-26       Impact factor: 10.247

Review 5.  Diagnosis and differential assessment of pulmonary arterial hypertension.

Authors:  Robyn J Barst; Michael McGoon; Adam Torbicki; Olivier Sitbon; Michael J Krowka; Horst Olschewski; Sean Gaine
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

6.  Effects of pathological flow on pulmonary artery endothelial production of vasoactive mediators and growth factors.

Authors:  Min Li; Kurt R Stenmark; Robin Shandas; Wei Tan
Journal:  J Vasc Res       Date:  2009-06-30       Impact factor: 1.934

Review 7.  [Animal models of pulmonary arterial hypertension].

Authors:  R Naeije; L Dewachter
Journal:  Rev Mal Respir       Date:  2007-04       Impact factor: 0.622

8.  Intrapulmonary shear stress enhancement: a new therapeutic approach in pulmonary arterial hypertension.

Authors:  Sayed Nour; Gang Dai; Daniel Carbognani; Minze Feng; Daya Yang; Nermine Lila; Juan Carlos Chachques; Guifu Wu
Journal:  Pediatr Cardiol       Date:  2012-05-06       Impact factor: 1.655

9.  Role for DNA damage signaling in pulmonary arterial hypertension.

Authors:  Jolyane Meloche; Aude Pflieger; Mylène Vaillancourt; Roxane Paulin; François Potus; Sotirios Zervopoulos; Colin Graydon; Audrey Courboulin; Sandra Breuils-Bonnet; Eve Tremblay; Christian Couture; Evangelos D Michelakis; Steeve Provencher; Sébastien Bonnet
Journal:  Circulation       Date:  2013-11-22       Impact factor: 29.690

10.  Role for miR-204 in human pulmonary arterial hypertension.

Authors:  Audrey Courboulin; Roxane Paulin; Nellie J Giguère; Nehmé Saksouk; Tanya Perreault; Jolyane Meloche; Eric R Paquet; Sabrina Biardel; Steeve Provencher; Jacques Côté; Martin J Simard; Sébastien Bonnet
Journal:  J Exp Med       Date:  2011-02-14       Impact factor: 14.307

View more
  1 in total

Review 1.  Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension.

Authors:  Sébastien Bonnet; Steeve Provencher; Christophe Guignabert; Frédéric Perros; Olivier Boucherat; Ralph Theo Schermuly; Paul M Hassoun; Marlene Rabinovitch; Mark R Nicolls; Marc Humbert
Journal:  Am J Respir Crit Care Med       Date:  2017-03-01       Impact factor: 21.405

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.